Cancer drug developer MacroGenics lines up March investor talks

robot
Abstract generation in progress

MacroGenics (Nasdaq: MGNX), a biopharmaceutical company focused on cancer therapeutics, announced its participation in four investor conferences in March 2026. CEO Eric Risser will deliver presentations and fireside chats, and management will hold one-on-one meetings. Webcasts of these events will be available on the company’s Investor Relations page.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin